Die Studie zur Gehirngesundheit: Eine pragmatische, patientenzentrierte Studie (eRADAR)
Kostengünstige Erkennung von Demenz mithilfe elektronischer Patientenakten: Validierung und Prüfung des eRADAR-Algorithmus (Risk of Alzheimer and Dementia Assessment Rule) für elektronische Patientenakten in einer pragmatischen, patientenzentrierten Studie.
The eRADAR Brain Health Study is an embedded, pragmatic clinical trial to determine whether targeted screening for dementia using the eRADAR algorithm increases dementia detection within primary care compared to usual care.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
eRADAR stands for "electronic health record (EHR) Risk of Alzheimer's and Dementia Assessment Rule." It is a low-cost tool or algorithm that uses readily available EHR data elements to identify patients at risk of undiagnosed dementia. The investigators will conduct a pragmatic randomized controlled trial to assess the impact of implementing eRADAR as part of a supported outreach process on dementia detection rates. The investigators will also explore the impact of eRADAR implementation on healthcare utilization and patient experience.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
California
-
San Francisco, California, Vereinigte Staaten, 94107
- UCSF Primary Care at China Basin
-
San Francisco, California, Vereinigte Staaten, 94115
- Division of General Internal Medicine
-
San Francisco, California, Vereinigte Staaten, 94143
- Women's Health Primary Care
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- No prior diagnosis of dementia (defined from EHR diagnosis codes) and not receiving medications for dementia
- Active patient at participating clinic
- Adequate data to calculate eRADAR score
Exclusion Criteria:
- Currently receiving hospice care
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Screening
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Brain Health Intervention
Participants in the intervention arm were invited to attend a "brain health" visit with a trained research interventionist who was a licensed clinician (e.g., social worker.) They were sent a mailed outreach letter and information sheet, with follow-up phone calls. At the visit, the research interventionist asked about memory symptoms and ability to perform instrumental activities of daily living (IADLs) and screened for cognitive impairment and depression. Results were shared with the participant and their primary care physician (PCP), who was responsible for follow up and more evaluation if needed and for making a final diagnosis of dementia, if applicable. |
Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. Research interventionalists will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended. |
|
Kein Eingriff: Usual Care
Individuals in this arm did not receive any intervention but rather usual care. University of California, San Francisco (UCSF) does not routinely screen for cognitive impairment (in line with current guidelines from the US Preventive Services Task Force). |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
New Diagnoses of Dementia (12 Months)
Zeitfenster: 12 months after index date
|
Number of patients who received new dementia diagnoses within 12 months, identified from the electronic health record (EHR) using a prespecified set of ICD-10 codes |
12 months after index date
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
New Diagnoses of Dementia or Mild Cognitive Impairment (12 Months)
Zeitfenster: 12 months after index date
|
Number of patients who received a new diagnosis of dementia or mild cognitive impairment within 12 months, defined from EHR data |
12 months after index date
|
|
New Diagnoses of Dementia (18 Months)
Zeitfenster: 18 months after index date
|
Number of patients who received a new diagnosis of dementia within 18 months of index date, defined from EHR data |
18 months after index date
|
|
New Diagnoses of Dementia (6 Months)
Zeitfenster: 6 months after index date
|
Number of patients receiving new dementia diagnoses within 6 months of index date, defined using EHR data |
6 months after index date
|
|
New Dementia Medications (12 Months)
Zeitfenster: 12 months after index date
|
Number of patients who received a new medication for dementia in 12 months, defined from medication orders or dispensings in the electronic health record |
12 months after index date
|
|
Urgent Care or Emergency Department Visits (12 Months)
Zeitfenster: 12 months after index date
|
Number of patients who had at least 1 urgent care or emergency department visit in the 12 months following their index date |
12 months after index date
|
|
Hospitalizations and Inpatient Admissions (12 Months)
Zeitfenster: 12 months after index date
|
Average number of hospitalizations and inpatient stays per participant within 12 months of index date |
12 months after index date
|
|
Scheduled Visits Missed (12 Months)
Zeitfenster: 12 months after index date
|
Average number of scheduled clinic visits missed ("no shows") per participant |
12 months after index date
|
|
Primary Care Visits (6 Months)
Zeitfenster: 6 months after index date
|
Average number of visits per participant in primary care within 6 months after the index date |
6 months after index date
|
|
Primary Care Visits (12 Months)
Zeitfenster: 12 months after index date
|
Average number of primary care visits per participant in the 12 months after their index date |
12 months after index date
|
|
B-12 Lab Tests (12 Months)
Zeitfenster: 12 months after index date
|
Number of patients with at least one B12 lab test in the 12 months after their index date |
12 months after index date
|
|
Neuroimaging Tests (12 Months)
Zeitfenster: 12 months after index date
|
Number of patients with at least one neuroimaging study (CT head, MRI brain) in the 12 months after their index date |
12 months after index date
|
|
Neurology Referrals (12 Months)
Zeitfenster: 12 months after index date
|
Number of patients with at least one referral to Neurology or the Memory and Aging Center in the 12 months after their index date |
12 months after index date
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Sascha Dublin, MD, PhD, KP Washington Health Research Institute
- Hauptermittler: Deborah Barnes, PhD, University of California, San Francisco
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Barnes DE, Zhou J, Walker RL, Larson EB, Lee SJ, Boscardin WJ, Marcum ZA, Dublin S. Development and Validation of eRADAR: A Tool Using EHR Data to Detect Unrecognized Dementia. J Am Geriatr Soc. 2020 Jan;68(1):103-111. doi: 10.1111/jgs.16182. Epub 2019 Oct 14.
- Lee SJ, Larson EB, Dublin S, Walker R, Marcum Z, Barnes D. A Cohort Study of Healthcare Utilization in Older Adults with Undiagnosed Dementia. J Gen Intern Med. 2018 Jan;33(1):13-15. doi: 10.1007/s11606-017-4162-3. No abstract available.
- Coley RY, Smith JJ, Karliner L, Idu AE, Lee SJ, Fuller S, Lam R, Barnes DE, Dublin S. External Validation of the eRADAR Risk Score for Detecting Undiagnosed Dementia in Two Real-World Healthcare Systems. J Gen Intern Med. 2023 Feb;38(2):351-360. doi: 10.1007/s11606-022-07736-6. Epub 2022 Jul 29.
- Dublin S, Greenwood-Hickman MA, Karliner L, Hsu C, Coley RY, Colemon L, Carrasco A, King D, Grace A, Lee SJ, Walsh JME, Barrett T, Broussard J, Singh U, Idu A, Yaffe K, Boustani M, Barnes DE. The electronic health record Risk of Alzheimer's and Dementia Assessment Rule (eRADAR) Brain Health Trial: Protocol for an embedded, pragmatic clinical trial of a low-cost dementia detection algorithm. Contemp Clin Trials. 2023 Dec;135:107356. doi: 10.1016/j.cct.2023.107356. Epub 2023 Oct 17.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 1R01AG069734 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
This Individual Participant Data (IPD) plan applies to all quantitative study data, such as data collected specifically for the study and those derived from electronic health records (EHR), as well as the data collected via planned study surveys, which include only short qualitative free-text fields. The investigators do not plan to share transcripts from in-depth qualitative interviews or recorded study assessment visits.
Data will be maintained on secure servers behind the firewalls at the University of California, San Francisco (UCSF). De-identified or limited datasets containing individual-level data on which publications are based will be made available to qualified researchers for specified analyses. The investigators will make the data available to users only under a data-use agreement (DUA).
IPD-Sharing-Zeitrahmen
Data can be requested after the primary study paper is accepted for publication, up until 5 years after study completion.
IPD-Sharing-Zugriffskriterien
Individuals interested in using data will be required to complete a standard form, sign a Data Use Agreement (DUA) and provide documentation of IRB approval. User registration will be required in order to access or download data files. As part of the registration process, users must agree to the conditions of use governing access to the data, including restrictions against attempting to identify study participants, destruction of the data after analyses are completed, reporting responsibilities, restrictions on redistribution of the data to third parties, and proper acknowledgment of the data resource. The UCSF Industry Contracts Division (ICD), which oversees incoming and outgoing transfer of all UCSF data, will review registration materials for compliance with UCSF policies.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .